The novel intratumoral agent JNJ-1900 (NBTXR3) activated by radiotherapy given in combination with anti–PD-1 immune checkpoint inhibitors (ICIs), including pembrolizumab (Keytruda) and nivolumab (Opdivo), demonstrated preliminary antitumor…
JNJ-190 Plus Anti–PD-1 Immune Checkpoint Inhibitors Generate Early Antitumor Activity in HNSCC
